Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44359   clinical trials with a EudraCT protocol, of which   7384   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,359 result(s) found. Displaying page 1,754 of 2,218.
    «« First « Previous 1750  1751  1752  1753  1754  1755  1756  1757  1758  Next» Last»»
    EudraCT Number: 2019-000312-28 Sponsor Protocol Number: P170901J Start Date*: 2019-12-18
    Sponsor Name:APHP / DRCI
    Full Title: Extending time without diabetes after bariatric surgery: a randomized controlled trial comparing the metformin addition or not to standard care
    Medical condition: Type 2 Diabetes complete remission after Bariatric surgery under antidiabetic drug
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004742-42 Sponsor Protocol Number: IFCT-1802 Start Date*: 2019-08-29
    Sponsor Name:IFCT
    Full Title: A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 t...
    Medical condition: Patient with a non small cell lung cancer and a poor general status
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    20.1 100000004867 10057364 Reduced general condition LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002145-37 Sponsor Protocol Number: 49RC19_0016 Start Date*: 2019-12-26
    Sponsor Name:University Hospital of Angers (CHU d'Angers)
    Full Title: MIVAR - Milrinone Infusion for VAsospam treatment in subarachnoid hemoRrhage
    Medical condition: hémorragies méningées ou sous-arachnoïdiennes avec vasospasme
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10047164 Vasospasm cerebral LLT
    20.1 100000004852 10042320 Subarachnoid hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001027-12 Sponsor Protocol Number: IsKPd-IFM2018-03 Start Date*: 2019-10-07
    Sponsor Name:CHU de Poitiers
    Full Title: Multicenter Open label Phase 2 study of Isatuximab plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003035-28 Sponsor Protocol Number: APHP200132 Start Date*: 2022-02-22
    Sponsor Name:Assistance Publique - Hôpitaux de Paris
    Full Title: " Combination of an Anti-PD1 antibody with Tisagenlecleucel Reinfusion in children, adolescents and young adults with Acute Lymphoblastic Leukemia after loss of persistence " CAPTiRALL
    Medical condition: Relapsed or refractory B-ALL (any relapse after HSCT, 2nd relapse or later, refractory ALL), aged 1-25 years old, previously treated by Tisagenlecleucel (Kymriah ®), Cohort 1 presenting early loss ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002334-36 Sponsor Protocol Number: 2018/350/HP Start Date*: 2021-12-02
    Sponsor Name:CHU de Rouen
    Full Title: VASCULAR AND RENAL IMPACT OF ENDOTHELIN-1 RECEPTOR BLOCKADE IN PATIENTS WITH RESISTANT ARTERIAL HYPERTENSION
    Medical condition: Resistant arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10038466 Renal hypertension and related conditions HLT
    20.0 100000004866 10038465 Renal hypertensions HLT
    21.1 10038359 - Renal and urinary disorders 10038464 Renal hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004785-19 Sponsor Protocol Number: ACT16877 Start Date*: 2021-04-01
    Sponsor Name:Sanofi-Aventis Recherche et Développement
    Full Title: A Phase 2, double-blind, randomized, placebo-controlled study assessing efficacy and safety of SAR441344, a CD40L-antagonist monoclonal antibody, in participants with relapsing multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    Population Age: Adults Gender:
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004332-30 Sponsor Protocol Number: ET18-291 Start Date*: 2020-04-24
    Sponsor Name:Centre Léon Bérard
    Full Title: LENVAGIST - A multicentre, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imati...
    Medical condition: Patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib (either on 3rd line treatment or beyond a 3rd line with regorafenib)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000060-22 Sponsor Protocol Number: 2020/0424/HP Start Date*: 2023-04-03
    Sponsor Name:CHU de Rouen
    Full Title: Comparison of a personalized maintenance therapy based on the evolution of anti-desmoglein antibodies as biomarkers of pemphigus subclinical activity, with the standard treatment (rituximab + corti...
    Medical condition: Pemphigus diseases (Pemphigus Vulgaris - PV and Pemphigus Foliaceus (PF).
    Disease: Version SOC Term Classification Code Term Level
    20.1 10015919 - Eye disorders 10067776 Ocular pemphigoid PT
    20.0 10040785 - Skin and subcutaneous tissue disorders 10034277 Pemphigoid PT
    21.1 10040785 - Skin and subcutaneous tissue disorders 10057052 Cicatricial pemphigoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001530-33 Sponsor Protocol Number: DR190041 Start Date*: 2019-06-29
    Sponsor Name:CHRU TOURS
    Full Title: TOPical sirolimus in linGUal microkystic lymphatic malformation-TOPGUN
    Medical condition: Lingual microcystic lymphatic malformations (LMLM) in children and adults
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10003229 Arteriovenous malformations LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002576-27 Sponsor Protocol Number: ICM-URC2016/27 Start Date*: 2017-03-01
    Sponsor Name:Institut régional du Cancer de Montpellier
    Full Title: Lean body mass normalization of oxaliplatin based chemotherapy for stage III colon cancer patients treated in adjuvant satting: Impact on Oxaliplatin induced sensitive neurotoxicity. A multicenter ...
    Medical condition: colon cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10009955 Colon cancer stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002396-34 Sponsor Protocol Number: APHP180605 Start Date*: 2019-12-23
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (APHP)
    Full Title: Antibioprophylaxis for excision-graft surgery in burn patient: a multicenter randomized double-blind study
    Medical condition: excision-graft surgery in burn patient with a TBSA% between 5% and 40%
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004863 10006764 Burn of unspecified site, unspecified degree LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003499-18 Sponsor Protocol Number: PI2022_843_0111 Start Date*: 2023-03-22
    Sponsor Name:CHU Amiens-Picardie
    Full Title: Is there a concordance between the Cellvizio with an intravenous injection of fluorescein and the pathology to determine the microscopic inflammation at the ileal resection margins in Crohn’s ileal...
    Medical condition: Crohn’s ileal disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-005748-12 Sponsor Protocol Number: 2012.761 Start Date*: 2013-04-26
    Sponsor Name:Hospices Civils de Lyon
    Full Title: D2 Resection and HIPEC (Hyperthermic intraperitoneal chemoperfusion) in locally advanced gastric carcinoma. A national randomized and multicentric phase III study
    Medical condition: Gastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10017770 Gastric carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000990-10 Sponsor Protocol Number: 2021-0201 Start Date*: 2021-07-22
    Sponsor Name:Institut de Cancérologie Lucien Neuwirth
    Full Title: FORMAT Study : Use of fibrinogen in the treatment of bleeding in thrombopenic patients after intensive chemotherapy refractory to platelet transfusion - evaluation by rotem viscoelastometry (pilot ...
    Medical condition: - Major patient; - Patient with malignant hemopathy requiring intensive chemotherapy, autologous or allogeneic hematopoietic stem cell transplantation; - Grade ≥ 1 hemorrhagic symptom according to ...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10066481 Hematological malignancy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001337-13 Sponsor Protocol Number: 2019-01 Start Date*: 2020-03-18
    Sponsor Name:GETAID
    Full Title: USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study
    Medical condition: patient with moderate to severe Crohn’s disease with at least one active perianal fistula track
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000850-78 Sponsor Protocol Number: IB2019-01 Start Date*: 2021-01-20
    Sponsor Name:Institut Bergonié
    Full Title: Atezolizumab combined with BDB001 and immunogenic radiotherapy in participants with advanced solid tumors.
    Medical condition: - pancreatic cancer - virus-associated tumors - non-small cell lung cancer - soft-tissue sarcoma - bladder cancer - Triple negative breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033605 Pancreatic cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10039494 Sarcoma NOS LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005012 Bladder cancer stage IV PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000883-42 Sponsor Protocol Number: APHP180614 Start Date*: 2021-01-18
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Impact of omalizumab withdrawal after a 3 year duration treatment in well controlled severe allergic asthma : a multicentric randomized controlled trial
    Medical condition: well controlled severe allergic asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001644-61 Sponsor Protocol Number: N/2016/73 Start Date*: 2018-06-07
    Sponsor Name:CHU Besançon
    Full Title: Efficacité en 1ère ligne de traitement d’une polychimiothérapie (méthotrexate, L-asparaginase, idarubicine et dexamethasone) dans la leucémie à cellules dendritiques plasmacytoïdes (LpDC) de l’adulte.
    Medical condition: leucémie à cellules dendritiques plasmacytoïdes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001229-15 Sponsor Protocol Number: 6398 Start Date*: 2019-04-16
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: Study of pimavanserin efficacy for the treatment of impulse control disorders in Parkinson's disease
    Medical condition: Impulse control disorders (ICD) in Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1750  1751  1752  1753  1754  1755  1756  1757  1758  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Sep 16 02:13:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA